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General Introduction  
Androgens and Androgen Receptor 
Androgens are steroid hormones derived from cholesterol and synthesised 
primarily in the testes prior to transport to target tissues (1). The main function of 
androgens is to mediate male phenotypic differentiation during the fetal period. During 
the neonatal period it also exerts effects upon the central nervous system, and during 
puberty and adulthood androgens have stimulatory effects on growth and functionality of 
the testes and the spermatogenesis. Although testosterone is one of two main androgen 
hormones, there is evidence that it might not be the active male sex hormone in certain 
tissues (2). Testosterone appears to be responsible for promoting the formation of the 
male reproductive structures (i.e., the epididymis, seminal vesicles, and vas deferens). 
However, it is not directly involved in the development of the male urethra, prostate, 
penis, or scrotum. Development of such tissues rely instead on 5α-dihydrotestosterone 
(DHT) which is converted to testosterone by 5-α reductase produced by basal and 
secretory luminal cells of the prostate and other sites as well, including liver.  
Androgen and the androgen receptor (AR) are essential for prostate development 
and proper function of the normal prostate (1). Binding of DHT to AR activates the 
receptor and, together with co-activators and co-repressors, regulates transcription of 
target genes. Approximately 80–90% of prostate cancers (PCa) are dependent on 
androgen at initial diagnosis, and endocrine therapy of PCa is directed toward the 
reduction of serum androgens and inhibition of AR function (3). Increased levels of 
testosterone or its metabolite, DHT, may increase risk for PCa (4), although such findings 
are inconsistent and controversial. For example, a nested cohort study of Norwegian 
subjects found no association between levels of DHT and PCa (5).  
In both the rat and human genome the gene encoding AR is located on the long 
arm of the X chromosome (q11-12) and consists of eight exons spanning a region of 170-
180 kb of genomic DNA (6) (See Figure 1). The promoter of the AR gene is a TATA-less 
type of promoter and contains GC-rich elements as bindings sites for the transcription 
factor Sp1 (7), a homopurine domain, a cAMP response element, and binding sites for 
other transcription factors (6). The original structural analysis of the AR protein revealed 
 6
that it contains four functional domains, similar to other members of the steroid receptor 
superfamily: a conserved DNA binding domain (DBD), a hinge region, a ligand-binding 
domain (LBD), and a less conserved amino-terminal domain (8,9). Further analysis of 
AR structure revealed two transcriptional activation function (AF) domains, including the 
N-terminal ligand-independent AF-1 domain and the C-terminal ligand-dependent AF-2 
domain. Upon binding of androgen to AR in the cytosol, the LBD undergoes 
conformational changes which result in a more compact structure (10). Parallel with this 
conformational change is the release of several previously bound molecular chaperones 
(e.g. hsp90 and hsp70) and the translocation of the receptor to the nucleus. The regulation 
of gene expression by AR requires the specific tethering of the AR homodimer to the 
promoter and/or enhancer sequences of target genes. Recognition and binding of AR to 
target genes is mediated by the DBD (amino acids 550–624), which is comprised of two 
zinc-binding modules, where four cysteine residues coordinate each Zn ion (6). The main 
features of the DBD are two α-helices positioned perpendicular to each other; of these the 
N-terminal helix is the ‘recognition helix’ and is positioned within the major groove of 
the DNA. This helix contains the key amino acids glycine 568, serine 569 and valine 572, 
which are collectively termed the ‘P-box residues’, and are directly involved in DNA 
sequence recognition. The P-box residues found within the AR are identical to those at 
the corresponding positions within the glucocorticoid, mineralocorticoid and 
progesterone receptors (6). 
 
 
FIGURE 1. AR gene organization and domain structure of the protein. The AR gene (top) consists of eight 
exons that give rise to the characteristic domain structure of the receptor protein (bottom). LBD, ligand-
binding domain; DBD, DNA-binding domain. Q and G represent polyglutamine and polyglycine repeats 
respectively. Figure from reference 6.  
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Androgen regulated genes  
Since prostate epithelial cells are highly androgen sensitive, they have been model 
systems for the identification of AR target genes (11). The most important androgen- 
regulated gene related to clinical application is Prostate Specific Antigen (PSA or 
Kallikrein 3) (12). PSA is a protease that is secreted from the prostate and may function 
in the liquification of the seminal fluid (13). Today PSA is used worldwide as a marker 
for PCa (14). However, because serum PSA levels differ significantly among men with 
no cancer, there is still strong debate among clinicians regarding its use as a marker for 
early cancer detection (15). Identification of better markers for early cancer detection that 
is more stable and specific than PSA is ongoing. Homeodomain-containing transcription 
factor 3.1 (NKX.3.1) is another androgen-regulated gene. NKX.3.1 is shown to interact 
with prostate-derived Ets factor (PDEF) a prostate-specific transcription factor that 
positively regulates PSA gene expression (16) and is thought to be essential for normal 
prostate development (17). The NKX.3.1 has previously been reported to map to 
chromosome band 8p21, which is a region frequently lost in PCa and in up to 78% of 
metastatic PCa cases NKX.3.1 expression is lost (18). However, new insight have 
questioned this view by the findings that there is no significant change in NKX3.1 mRNA 
levels during prostate cancer progression which suggests that NKX3.1 may not be 
associated with the allelic loss (19). Recently, microarray technology has been used to 
identify a large number of  novel androgen-regulated genes involved in protein folding, 
trafficking and secretion, metabolism, the cytoskeleton, cell-cycle regulation and signal 
transduction (6). As expected, a common feature of AR-regulated genes is the presence 
of one or more Androgen Response Elements (AREs) AR or hormone response elements 
(HRE), together with binding sites for housekeeping genes, and inducible and tissue-
specific transcription factors. Thus, androgen-regulated gene expression is likely to 
involve the coordinated interactions of the receptor protein as well as many other 
transcription factors.  
 
 8
Androgen regulation of lipid metabolism 
The group of Guido Verhoeven was the first to report that androgens regulate 
lipid metabolism genes in the LNCaP prostate cancer cell line (20,21). Later they found 
more direct evidence by the observation that exposure of LNCaP cells to androgens lead 
to massive accumulation of neutral lipids (triglycerides and cholesteryl esters), which are 
storage products of fatty acid and cholesterol (22). In support for involvement of 
androgen receptor the androgen antagonist Casodex (bicalutamide) abolish the 
stimulatory effects of androgens and do not change the lipid profile in AR-negative 
prostatic cell lines. Analysis of the origin of the accumulated lipids revealed that these 
lipid accumulations are the result of a major androgen-induced increase in the synthesis 
of fatty acids and of cholesterol, the majority of which is used for membrane synthesis 
(22). Induced synthesis of fatty acids and cholesterol is governed by androgens through 
stimulation of the expression of whole sets of lipogenic enzymes, covering the entire 
pathways of fatty acid and cholesterol synthesis (23). Key players in the regulation of 
these pathways are the sterol regulatory element binding proteins (SREBPs). SREBPs are 
a family of three basic helix–loop–helix leucine zipper lipogenic transcription factors 
(SREBP-1a, SREBP-1c, SREBP-2) that are synthesized as inactive precursor proteins 
anchored to the membranes of the endoplasmic reticulum (ER) (24). There they interact 
with an SREBP-cleavage-activating protein (SCAP), which is retained in the ER by Insig 
retention proteins (25,26). The SCAP/SREBP/Insig complex is stabilized by cholesterol. 
When sterol levels are low, the SREBP–SCAP complex is released from the Insig 
retention protein and travels to the Golgi apparatus where an amino-terminal SREBP 
fragment is released by a two-step mechanism of regulated intramembrane proteolysis. 
This transcriptionally active fragment is translocated to the nucleus and depending on the 
SREBP isoform activates the transcription of multiple genes involved in the synthesis, 
binding, metabolism and uptake of fatty acids and cholesterol.  
Mounting evidence demonstrates that the primary sites of action of androgens on 
the SREBP pathway are SCAP and Insig retention proteins (see figure 2). Androgens 
markedly stimulate the expression of SCAP and cause a switch in the isoform expression 
of Insig (27). This results in a change in the balance of the SREBP–SCAP complex on 
one hand and the retention protein complex on the other hand. The fraction of SCAP that 
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is not retained by the retention protein would be free to escort the SREBP precursor to the 
Golgi apparatus leading to proteolytic maturation and activation of lipogenic gene 
expression. Androgens also stimulate the expression of SREBP-1c and SREBP-2 
precursors, but these effects are thought to be secondary to the proteolytical activation of 
SREBPs. A similar mechanism of action as described for androgens has been proposed to 
explain the lipogenic effects of progestagens in adipocytes and in breast cancer cells (28). 
 
 
FIGURE 2. Androgens stimulate lipogenic gene expression. Lipid homeostasis in mammalian cells is 
largely regulated by the SCAP/SREBP pathway. Sterol regulatory element-binding proteins are lipogenic 
transcription factors, synthesized as inactive precursors. SREBPs interact with SCAP, a SREBP cleavage-
activating protein, which functions as a cholesterol sensor and which is retained in the ER by Insig 
retention proteins. Androgens stimulate the expression of SCAP and modulate the balance of SCAP and the 
Insig protein. Part of the SCAP pool is not retained by Insig and escorts the SREBP precursor to the Golgi, 
where a set of proteases cleaves the SREBP precursor. The amino-terminal fragment is released and is 
translocated to the nucleus where it binds to SREBP-binding sites (SREBP-BS) in numerous genes involved 
in lipid metabolism and activates their transcription. Figure from reference 21.  
 
The prostate 
The prostate is located in the pelvis, posterior to the bladder and superior to the 
rectum.  The normal function of the prostate gland is not clearly understood but it 
produces seminal fluid and may facilitate sperm motility (29). The prostate is a network 
of  branching glands, composed of ducts lined with secretory epithelial cells and basal 
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cells. Scattered neuroendocrine cells are also present and are thought to provide a 
paracrine function in the gland (30). Secretory epithelial cells represent the major cell 
type in the gland. They are androgen-dependent for growth, and secrete PSA. The basal 
cell layer is not dependent on androgen for growth and is believed to contain the stem cell 
population for the epithelial prostate cells. Surrounding the gland is a stroma that includes 
fibroblasts, smooth muscle, nerves, and lymphatic cells (31).  
 
Prostate Cancer  
Prostate cancer is the second most commonly diagnosed cancer in men in the US 
and Western Europe that leads to significant numbers of death or impaired quality of life. 
The estimated annual incidence in 2000 was 543,000 cases worldwide (32). The number 
of incidents in 2005 is predicted to be 232 080 in the United States alone (33). In Norway 
the age-adjusted incident rate was 76 cases per 100,000 inhabitants in 2001 (34). In the 
US the lifetime risk for PCa is 1 in 6, and the risk for development to metastatic PCa is 1 
in 30 (35). The incidence of PCa has increased in the past 50 years, with recent dramatic 
increases most likely due to early detection methods, such as the measurement of serum 
PSA, rather than true differences in underlying risk (36). 
The transformation of the prostate from a normal to an aggressive hormone 
insensitive cancer state is a complicated process that is still not fully understood. In 
recent years, a more comprehensive picture of the physiological and molecular state of 
the disease has been revealed. Briefly, three different cellular origins for prostate cancer 
have been postulated (37). In the first scenario, androgen-independent basal stem cells 
acquire somatic genetic changes which results in continuous growth stimulation. 
Alternatively, the tumour can arise from androgen-independent cells from this basal 
layer. In both scenarios, such cell types are potential cancer origin cells. Acquisition of 
AR expression in these cells confers androgen dependent growth properties. Androgen 
ablation therapy is effective at eliminating cells, but leaves androgen- independent basal 
cells intact. Growth of androgen-independent cells is thought to give rise to malignant 
growth. The reduction of serum and prostatic DHT levels by castration also results in a 
loss of 70% of the prostate secretory epithelial cells due to apoptosis, but the basal 
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epithelia and stromal cell populations are relatively unaffected (38). As a consequence, 
low circulating amounts of androgen will allow continued proliferation of the precursors 
to reach a hormone refractory state. Finally, in a third scenario, prostate cancer might 
originally develop from an AR positive luminal cell. Such a cancer could be completely 
abolished by ablation therapy but due to the genetic instability of cancer cells, some of 
the androgen-dependent cells somehow lose their dependency on androgen to become 
androgen-independent (37). By the time of PCa diagnosis, prostate cells may have 
undergone many somatic mutations, gene deletions, gene amplifications, chromosomal 
rearrangements, and changes in DNA methylation patterns. These alterations probably 
accumulate over a period of several decades (39).   
 
Risk factors for prostate cancer 
Despite its importance, the cause of PCa development is still not well understood. 
Nutrition and diet is believed to play an important part, but other factors also influence 
(36). In general, risk factors for PCa can be divided into two categories: the endogenous 
factors that consist of family history, hormones, aging, oxidative stress and race, and 
exogenous factors are related to diet, environmental factors and exercise. A more detailed 
discussion of some the most relevant risk factors follow below.  
 
Family history. PCa appears to have a stronger familial aggregation than colon or 
breast cancer, two malignancies with well recognized familial components (36). There is 
a reported 2- to 4-fold increased risk among men whose father or brother were also PCa 
patients after adjustment for age and dietary factors (40). Polymorphic variation in the 
trinucleotide repeat lengths of the AR NH2-terminal is associated with altered AR 
transcriptional activity in vitro (41), and may also contribute to PCa risk or progression. 
 
Age and oxidative stress.  The frequency of PCa increases dramatically with age, 
beginning with low frequencies in middle-aged men and progressing to >90% by the age 
90 (42). During aging there is a progressive accumulation of DNA adducts and an 
increase in DNA frequency strand-breaks in most tissues (43). It is believed that these 
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age-related changes are caused by accumulation of oxidative stress (44). Energy 
metabolism has for many years been coupled to oxidative stress by generation of reactive 
oxygen species (ROS). During cellular respiration in the mitochondria ROS can 
occasionally be generated as by-products (45,46). ROS are highly reactive and potentially 
damaging to cells because they directly impair macromolecule structure and organelle 
function. Improper disposal of ROS can lead to greater genomic instability. Whether the 
prostate accumulates more ROS than other tissues remains an unanswered question.  
 
Race – There is reportedly large differences in PCa incidence among various 
races. Between 1988 and 1992, race-specific incidence rates in the U.S. ranged from 24.2 
per 100, 000 for Koreans, 89.0 per 100, 000 for Hispanics, 134.7 per 100, 000 for whites, 
and 180.6 per 100, 000 for African Americans. Black men in the U.S. are more likely to 
present with advanced-stage cancers than white men, and their stage-specific mortality is 
significantly greater, especially among younger men (36). In the last few years, a large 
increase in incidence in Asia has been observed, and has been explained by the 
adaptation of lifestyle and diet habits more similar to western countries. Japanese 
immigrants to the U.S. for example, have a higher incidence rate than native Japanese.   
 
Diet. Dietary fat is a strong risk factor for PCa (47). A large body of descriptive 
epidemiological studies of migrants, geographic variations, and temporal studies supports 
the hypothesis that dietary factors may contribute to PCa development. However, not all 
studies have found an association between dietary factors and PCa risk (48). A cohort 
study measuring fat intake did not note any connection between increased fat intake and 
the risk of advanced PCa (49). It is unclear how dietary fat may increase the risk of PCa, 
but a number of mechanisms have been proposed. These include dietary fat-induced 
alterations in hormonal profiles, the effect of fat metabolites as protein or DNA reactive 
intermediates, and dietary fat-induced elevation of oxidative stress. It is likely that the 
relationship between dietary fat and PCa risk is complex, involving interplay of fat with 
other dietary factors, such as antioxidants, vitamins and minerals, as well as genetic 
factors that influence disease susceptibility (36). There is a growing body of evidence that 
obesity is related to others malignancies as well, especially colon cancer and post 
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menopausal breast cancer (50). But also PCa has been associated with obesity (Ref). 
Since a major goal of this thesis is to understand how obesity is a risk factor leading to 
cancer, a basic understanding of the nature of obesity is necessary, described below.  
 
Lipogenesis in prostate cancer  
In recent years, numerous reports have demonstrated overexpression of lipogenic 
enzymes such as fatty acid synthase (FAS) and acetyl-CoA carboxylase, in a wide variety 
of cancer types including cancer of the breast, endometrium, ovaries, lungs, colon, oral 
cavity, several soft tissues, and the prostate, (reviewed in (51)). In the prostate, 
overexpression of FAS has been studied most intensively and is found in the earliest 
stages of neoplastic transformation (PIN lesions) and in nearly all invasive carcinomas 
(52-54).  
How and why lipogenic proteins are overexpressed in prostate cancer cells 
remains poorly understood. With respect to the mechanism underlying high level 
expression of FAS, it is evident from the earlier mentioned observations that androgens 
and dysregulated androgen receptor function play an important role. In LNCaP prostate 
cancer cells it has been shown that a mutation in the tumor suppressor gene encoding 
Phosphatase and Tensin Homolog Deleted on Chromosome Ten (PTEN) leads to 
constitutive Akt signaling and substantially contributes to the high level expression of 
FAS. Exposure to growth factors such as epidermal growth factor (EGF) further enhances 
lipogenic enzyme expression (55).  Similar to the lipogenic effects of androgens, growth 
factor-induced lipogenesis is in part governed at the transcriptional level and involves 
activation of SREBPs. In several instances the effects at the protein level are more 
pronounced than those at the transcriptional level, suggesting that translational and/or 
post-translational effects further enhance lipogenic enzyme expression and activity 
(53,56) 
In most tumor cells examined the majority of newly synthesized lipids are 
phospholipids (54,57). As phospholipids are the major building blocks of membranes it 
has been speculated that increased lipogenesis in cancer cells reflects the high rate of 
membrane synthesis in rapidly dividing cells. In most clinical prostate cancers, however, 
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only a fraction of the cancer cells are at one moment engaged in an active cell cycle, 
while nearly all cancer cells express high levels of FAS (52). Moreover, in contrast to the 
lipids derived from the diet which are relatively rich in polyunsaturated fatty acids, the 
newly synthesized phospholipids are enriched in saturated and in monounsaturated fatty 
acyl chains (57). Together with cholesterol these phospholipids tend to partition into 
detergent-resistant membrane microdomains (57,58). These are raft-aggregates 
implicated in key cellular processes including intracellular trafficking, signal transduction 
and cell migration (59). Hence, it is expected that increased lipogenesis in cancer cells 
affects multiple key aspects of tumor cell biology and actively contributes to the 
development and the progression of cancer. 
So far we have discussed androgens and AR as important factors for prostate 
cancer progression and growth. Androgens induce synthesis, metabolism and transport of 
fatty acids and cholesterol activating a whole set of lipogenic enzymes which is highly 
upregulated in PCa. Epidemiological and molecular evidence connects PCa and high fat 
diet but a connection between up-regulation of lipogenic protein and diet has not been 
confirmed in PCa. A growing body of evidence does however link obesity to  
malignancies, especially colon cancer and post menopausal breast cancer, and PCa also 
has been associated with obesity (50). Since a major goal of this thesis is to understand 
how obesity is a factor leading to cancer, a basic understanding of the nature of obesity is 
necessary as reviewed below. 
 
Obesity  
Obesity is defined medically as a state of increased body weight, more 
specifically adipose tissue, of sufficient magnitude to produce adverse health 
consequences (60). The most widely used index of obesity is the body mass index (BMI), 
calculated by dividing the body weight in kilograms by the square of the height in meters 
(kg/m2). According to this system, people with a BMI of 18.5 to <25 is considered to be 
of normal weight, BMI of 25 to <30 are considered “overweight” and  BMI 30 are 
considered “obese” (50). Obesity has reached epidemic proportions globally and 
continues to increase. In the US, the prevalence of obesity rose from 12 to 20% between 
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1978 and 1990 (61). In Norway, a population-based study among men during a two year 
period showed an increase in obesity from 9.6 to 14% (62).  
The increase in obesity during the last 30 years is associated with a dramatic 
increase in prevalence of serious health conditions, such as type 2 diabetes. Globally, the 
number of people with diabetes is predicted to rise by almost 50% in 10 years from 151 
million in the year 2000 to 221 million in 2010 (63). The most potent predictor for the 
risk of diabetes, apart from age, is BMI. A high BMI is also associated with higher blood 
pressure and risk of hypertension, higher total cholesterol, LDL cholesterol, triglyceride 
levels, and lower HDL cholesterol levels. The overall risk of coronary heart disease and 
stroke, therefore, increases substantially with weight gain and obesity (63). 
Obesity results from an imbalance between energy expenditure and energy intake. 
The epidemic of obesity is clearly related to nutrition and energy intake (64), and the 
underlying cause is thought to be a combination of excess caloric intake and insufficient 
physical activity (65). Nevertheless, many individuals manage to resist obesity. 
Accordingly, a key goal of ongoing research in this field is to identify mechanisms by 
which environmental factors interact with specific genes, either to promote, or facilitate 
resistance to obesity.  
Energy expenditure can be divided into three major components. The largest of 
these is the necessary energy spent on basic cellular and physiologic functions that 
require ATP, followed by physical activity and the diet induced thermogenesis (50). The 
first of these, basal metabolism, is related to the types of foods eaten, adaptive capacity of 
the body and rate of energy expenditure. The maintenance of energy balance requires that 
the body oxidizes the food eaten. The capacity for storage of carbohydrate is very limited, 
and the capacity to store protein is also restricted (50). Only fat stores can readily expand 
to accommodate increasing levels of energy intake above those required for daily energy 
needs. Secondly, energy expended in physical activity is directly related to body weight. 
Physical activity gradually declines with age, and maintaining a regular exercise program 
is difficult for many people, particularly as they get older. Adaptation to a change from a 
low- to a higher-fat diet takes time and can be accelerated by exercise (66). The thermic 
effect of food is the third component of energy expenditure (50). After food is ingested, 
there is a rise in energy expenditure, which accounts for approximately 10% of the day’s 
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energy expenditure. The sympathetic nervous system controls part of this process. The 
control of sympathetic activity and its noradrenergic output offers a possible strategy for 
treating obesity by raising energy expenditure. Brown adipose tissue (BAT), which is rich 
in the uncoupling protein 1 (UCP1), has a well established role in temperature and body 
weight regulation in rats and mice (67). Increased expression or activation of this protein 
uncouples oxidative phosphorylation, resulting in the conversion of energy to heat. The 
importance of this molecule in humans has always been questioned because of the very 
low levels of brown fat in adult humans. Recently the identification of two additional 
uncoupling proteins (UCP2 and UCP3) that are highly expressed in adult human muscle 
tissue has attracted considerable interest. Nonetheless, many think that these proteins are 
not critical for involvement in whole body energy expenditure because energy 
homeostasis is normal in mice lacking both proteins (68,69). However, they are under 
heavy focus especially related to calorie restriction (CR) which will be covered in detail 
below.  
 
The Endocrine System and Obesity 
The endocrine and autonomic nervous systems are major efferent control systems 
involved in regulating appetite and energy storage (see figure 3). The hypothalamus is the 
primary locus for integration of the various signals secreted from the adipose tissue, 
gonads, intestine or pancreas. Several critical hypothalamic circuits and signalling 
pathways are reported so far (64). Three major endocrine components involved in obesity 
are the intestine, the pancreas and the sex hormone secreting gonads; these will be 
covered briefly below, while the white adipose tissue (WAT) will be extensively 
discussed. 
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FIGURE 3. The energy balance system involves long-term afferent signals from fat (leptin) and pancreatic 
β cells and short-term, meal-related afferent signals from the gut, including inhibitors of feeding (GLP-1, 
and CCK), and the stimulator of feeding (ghrelin). These inputs are integrated within the brain. Efferent 
outputs regulate appetite, energy expenditure, hormonal milieu, energy partitioning, and the status of 
reproduction and growth. Figure from reference 64.  
 
WAT is an important component of the body’s system of energy balance and 
therefore plays a central role in obesity and type 2 diabetes (60). Until the 1980s adipose 
tissue was viewed to function as a depot for fat in the body where hormone stimulation 
would change lipid balance in the tissue. Discoveries made since then have 
revolutionized this concept and adipose tissue is now thought to also function as an 
important part of the endocrine system. Adipose tissue is dispersed throughout the body 
but accumulates in loose connective tissues positioned subcutaneously between muscles 
and dermis. Fat also surrounds every internal organ (70). Nearly all initial work on 
adipocytes was conducted in mouse preadipocyte fibroblast cell lines such as 3T3-L1 and 
3T3-F442A, both of which can be induced to differentiate into adipocytes (71). In general 
this in vitro model system is thought to faithfully recapitulate in vivo adipocyte 
differentiation. However, one striking difference is that molecules secreted by the 
adipocyte, leptin and tumor necrosis factor α (TNF-α), are poorly expressed in these cell 
lines compared to adipocytes in vivo. More recently, studies have been performed using 
pluripotent mesenchymal stem cells that can be induced to yield adipocytes in addition to 
cells of several other lineages. Other studies have also been carried out in mouse models 
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in which important adipose genes were overexpressed or knocked out. Adipsin, 
adiponectin, TNF-α, leptin, and plasminogen activator inhibitor-1 are all produced by 
adipocytes (72-79). Interestingly, these factors can be regulated by feeding, fasting and 
obesity (80-82). Among the adipocytokines, leptin is probably the most well 
characterized. Leptin is a 16-kDa protein and was initially viewed as an adipocyte-
derived signal that functioned primarily to prevent obesity by controlling satiety. It is 
now understood that leptin also serves as an important signal generated by adipose tissue 
to inform the brain, by falling below threshold amounts, that the body is starving (83); 
this function is likely as important or perhaps even more so, than its antiobesity role (64). 
In obese patients with functional ob genes, leptin levels are increased in proportion to 
body fat (84), and this hyperleptinemia reflects a state of leptin resistance. The 
mechanism for resistance to the weight reducing effects of leptin in obesity has received 
considerable attention, but is still unclear ten years after initial identification of the leptin 
receptor (85). Resistance to leptin action is typical in obesity, but is a less severe 
condition than that seen in rare cases where the receptor is totally lacking. There is 
therefore increased interest in the precise signalling pathways downstream of the leptin 
receptor that mediates its actions on energy balance and endocrine function. Initial 
attention focused on the JAK/STAT intracellular signalling pathway and its regulation of 
gene expression. However, additional pathways downstream of JAK, including MAP 
kinase and PI3 kinase, that are also capable of being activated by leptin in vitro and in 
vivo are being considered (86). 
Adiponectin is an adipocyte-secreted protein that circulates at a high 
concentration in plasma (79). Levels of adiponectin are reduced during obesity, and the 
suppression correlates with insulin resistance in obesity and related disorders (87). 
Replacement of deficient adiponectin has a variety of beneficial effects, including 
reducing glucose and lipid levels, increasing lipid oxidation rates, and maintaining 
vascular tone (88). Adiponectin appears to act in part by activating the enzyme AMP 
kinase (89). Levels are also induced by treatment with anti-diabetic thiazoladinediones 
(TZDs) (90). The cognate receptor for adiponectin has recently been identified (91), and 
its physiologic role is receiving great attention. 
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 The first stage of differentiation from fibroblasts into fat cells involves growth 
arrest achieved by cell-cell contact inhibition. Addition of prodifferentiative hormones 
stimulate a few cycles of cell division and activate the transcription factors Peroxisome 
Proliferator Activating Factor γ (PPARγ) and CCAAT/Enhancer Binding Protein α 
(C/EBPα). These transcription factors bring the cells to permanent growth arrest and start 
the transcriptional regulation of a number of important genes essential for development to 
a fully differentiated adipocyte phenotype (71). Some of these genes are 
glycerophosphate dehydrogenase (GAPDH), fatty acid synthase (FAS), acetyl CoA 
carboxylase (ACC), malic enzyme, glucose transporter 4 (Glut 4), the insulin receptor 
(IR), and adipocyte-specific fatty acid binding protein 2 (aP2) (92).   
PPARγ is a member of the nuclear receptor protein subfamily that form 
heterodimres with the retinoid X receptor (RXR). It regulates genes by binding to 
response elements as a heterodimer complex with RXRs (93). PPARγ exists in two 
isoforms that are created by alternative promoter usage and alternative splicing at the 5' 
end of the gene. PPARγ2 contains 30 additional amino acids at the N terminus compared 
with PPARγ1 (94). While many tissues express low levels of PPARγ1, PPARγ2 is highly 
fat-selective and is expressed at very high levels in this tissue (95). Use of the high-
affinity, selective PPARγ agonist TZD or mice null for PPARγ have been important for 
establishing PPARγ as the most important factor for adipogenesis (71).  
C/EBP proteins are basic-leucine zipper transcription factors. They act as homo- 
or heterodimers, and their tissue distribution is not limited to adipose tissue (96). 
However, regulation of the expression of several C/EBP family members is seen during 
adipogenesis, and recent gain- and loss-of-function studies indicate that these proteins 
have a profound impact on fat cell development. In cultured preadipocytic cell lines that 
have been induced to differentiate, C/EBPβ and δ mRNA and protein levels rise early and 
transiently. C/EBPα, on the other hand, is induced later in the differentiation process, 
slightly preceding the induction of most of the end-product genes of fat cells (97). The 
emerging picture is therefore that C/EBPβ and δ induce the expression of PPARγ by 
direct binding to the promoter of PPARγ which then induces expression of C/EBPα (71). 
The whole picture has become more complicated recently as new factors are discovered 
to play important roles during adipogenesis.  These include transcription factors such as 
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adipocyte determination and differentiation factor 1 / sterol regulatory element-binding 
protein 1 (ADD1/SREBP1) (98), PPARδ (99) , retinoic acid receptor-related orphan 
receptor-γ (RORγ) (100) , estrogen receptor-related receptors α (ERRα) (101), GATA-2 
and GATA-3 (102).  
The literature concerning extracellular and intracellular signals that influence 
adipogenesis is enormous. Only some major pathways that likely are of great importance 
will be discussed below. Insulin is a product of the pancreatic β cells, but induces major 
effects upon adipose tissue. Insulin is required for differentiation into adipocytes in vitro 
and also increases the accumulation of lipids inside the cells (103). Since adipocytes 
express few insulin receptors, cross- activation of the Insulin like Growth Factor -1 (IGF-
1) receptor is the most likely target for the hormone (71). IGF-1 and insulin induce 
expression of Ras and protein kinase B (PKB or Akt) which both strongly induce further 
differentiation via downstream signalling (71). Glucocorticoids also stimulate 
adipogenesis by activating the glucocorticoid receptor (GR) which has been shown to 
induce expression of C/EBPδ (104). Many cytokines and growth factors have been shown 
to inhibit fat cell development. The most studied candidates are TNF-α, interleukin 1 (IL-
1), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and epidermal 
growth factor (EGF). Their downstream effector are most likely the mitogen activated 
protein (MAP) kinases, such as extracellular-signal regulated kinase (ERK1 and 2) and c-
Jun N-terminal Kinase (JNK); it is interesting to note that JNK phosphorylates and 
inactivates PPARγ2 and RXR (105,106).  
 The gonads that secrete the sex steroids (testosterone and estrogens), are known to 
influence body composition, although the molecular mechanisms and their involvement 
in energy expenditure is not well understood (50). At puberty, the production of 
testosterone in males is associated with a reduction in the percentage of body fat (107). 
Testosterone increases lean mass relative to fat, and estrogen has the opposite effect. 
Testosterone levels fall when men grow older, and there is a corresponding increase in 
visceral and total body fat and a decrease in lean body mass. This may be compounded by 
the decline in growth hormone that is also associated with an increase in fat relative to 
lean mass. Both androgens and estrogens are involved in obesity and fat distribution. In 
females, the increase in estrogens is involved in the remodelling that produces the female 
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shape. When the ovaries are removed surgically in animals, obesity frequently develops 
and can be reversed by giving injections of estradiol. The importance of this mechanism 
has been highlighted by the study of animals with transgenic defects in their hormone 
receptors. Animals without estrogen receptor α are obese (50). Studies have also shown 
that testosterone inhibits lipid uptake and lipoprotein-lipase (LPL) activity in adipocytes. 
Moreover, testosterone stimulates catecholamine-induced lipolysis by increasing the 
number of beta-adrenergic receptors (108,109). An indirect sign of these effects is the 
decrease of adipocyte leptin production. Leptin, as described above, stimulates the brain 
to trigger a “stop eating” reaction, but can also act to prevent fat accumulation in non-
adipose tissue by increasing mitochondrial oxidation of fatty acids (110). The fact that 
high leptin levels prevalent in hypogonadal men are reduced by testerosterone 
replacement therapy, offers further indication of lipolytic effects of testosterone (111). 
Testosterone also inhibits the differentiation of adipocyte precursor cells. In a study of the 
effect of sex hormones effect on rat adipogenesis, androgens (testosterone, DHT, 
androstanediol, and androstenediol) were shown to have no effect on the preadipocyte 
growth in male rats (112). Moreover, testosterone and DHT did not change PPARγ2 
expression in male rats, suggesting that these androgens are negative effectors of 
preadipoctye maturation. 
  The intestine secretes factors that stimulate the energy homeostasis in various 
ways. One of the gastrointestinal peptides that have been studied as potential regulators of 
satiety is cholecystokinin (CCK). This was one of the first peptides shown to reduce food 
intake in both rodents and humans (113). CCK is released from the small intestine into 
the circulation in response to luminal nutrients such as fatty acids, and influences satiety 
by acting on CCK receptors located on peripheral vagal afferent terminals, which 
transduce neural signals to the brainstem. Ghrelin is another peptide that was recently 
discovered to be produced in the stomach. It is believed to be the natural ligand for the 
growth hormone secretogogue receptor (114). This peptide stimulates food intake and 
with repeated administration will produce obesity. Its concentrations are lower in the 
serum of obese versus lean subjects, but in both cases there is a decrease with food intake. 
 Several pancreatic peptides modulate feeding. Both glucagon and its 6–29 amino 
acid analogue, glucagon-like peptide-1 (GLP-1), reduce food intake in animals and 
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humans (115). GLP-1 also enhances the release of insulin by the pancreatic beta cell in 
the presence of glucose. Analogs or small molecules that might influence GLP-1 receptor 
release or duration of action would be interesting for treating both obesity and diabetes. In 
addition to the direct impact on adipose differentiation, insulin also affects food intake 
and is the master metabolic switch between the fed and fasted states with regard to 
metabolic fuel deposition and use. The levels of insulin are well known to fall with 
fasting, and rise with obesity, similar to leptin (64). This led to the proposal many years 
before the cloning of the ob gene, that insulin might be the dominant signal of fuel status 
to the brain (116). When brain insulin levels increase, food intake is reduced. When the 
insulin receptor in the hypothalamic part of the brain is disabled by antisense 
oligonucleotides, animals eat ravenously (117).  
 
Calorie restriction  
The opposite of obesity is food scarcity. Although not intuitively thought of as 
healthy,  pioneering intensive work during the 1930s in the model organism 
Saccharomyces cerevisiae, and later Caenorhabitis elegans and Drosophila 
melanogaster, have led to the theory that calorie restriction (CR) in fact extends life span 
(118). Early in the birth of this field a link between CR and decreased generation of ROS 
was suggested. Oxygen radicals are highly reactive chemical species that carry an 
unpaired electron, which can damage surrounding macromolecules, lipids, proteins and 
DNA. In eukaryotes, mitochondria are the prime site of ROS generation, because 
complex I and complex III of the electron transport chain occasionally generate these 
toxic by-products during normal respiration. ROS is strongly implicated in several 
diseases, such as prostate cancer (as discussed above). A molecular model for how CR is 
related to aging is still in early phases but there is strong evidence that it requires proteins 
coded by the genes in the sirtuin family (119). These are NAD dependent histone-
deacetylases with sequence similarity to the yeast Sir2 gene. Early studies suggested that 
adiposity was not an important factor in determining the lifespan of rodents (120), but 
more recent findings show that mice that have been genetically engineered to be lean live 
longer (121). In a breathtaking study by Picard et al., the mammalian homolog of Sir2, 
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SIRT1, was shown to inactivate PPARγ in WAT by docking to the negative cofactors of 
the nuclear receptor and thereby downregulating genes for adipogenesis, such as aP2 
(122). When taken together with the finding that calorie restricted fat cells secrete less 
TNF-α and more adiponectin, concomitant with increased insulin sensitivity and 
decreased glucose uptake, these data suggest a proposed pathway for CR where SIRT1 is 
activated in WAT by food scarcity with the consequence that the fat stores are reduced. 
This changes the hormone levels to a more physiologically favourable state (119). 
 
 
FIGURE 4. Calorie restriction, SIRT1 and WAT. Under ad libitum (or freely fed) conditions, the 
fat-specific nuclear hormone receptor PPARγ transcribes the aP2 gene, which encodes a protein that binds 
to triglycerides and thereby assists fat storage (pink droplet). Under calorie-restriction conditions, SIRT1 
binds to PPARγ at the aP2 promoter in white adipose tissue, thereby repressing PPARγ activity, lowering 
the expression of PPARγ target genes such as aP2, and reducing fat storage. Figure obtained from 
reference 119. 
 
 Although SIRT1 seems to have an important function during life span regulation, 
it does not explain the connection between ROS and CR. The uncoupling proteins on the 
other hand are good candidates as they were shown to be positively correlated to lifespan 
(123). UCPs are believed to function in the mitochondria where their function is to 
partially depolarize the mitochondria membrane by lowering the proton gradient, and 
potentially reduce the rate of generation of oxidative damage (124). In small animals like 
rodents, CR may up-regulate UCPs assuming it is advantageous for the animal to use a 
greater portion of the energy to produce heat.  
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Obesity and PCa 
Epidemiological evidence of a relationship between obesity and PCa is lacking. A 
study of 135, 000 Swedish construction workers found a positive correlation but a 
stronger relationship to mortality than incidence (125). A recent study from 47, 781 
American men showed that a body mass index of more than 30 kg/m2 (ie, the obese state) 
in men younger than 60 yrs and with a familiy history of PCa was associated with a lower 
risk of PCa compared to that of BMI 23-24.9 kg/m2.  For more sporadic cancers, BMI had 
a non-statistically significant positive correlation to PCa (126). However, a growing body 
of evidence from population-based studies supports the hypothesis that obesity may 
influence the development and progression of PCa. An attempt to estimate the rate 
obesity increases the risk for PCa suggests a 6% increase in risk of PCa for an overweight 
man compared with a normal weight and a 12% increase in risk for an obese man. This 
indicate that 4% of European men with PCa is attributable to this cause, corresponding to 
5000 new cases a year (127). A different  estimate for the US showed that men with a 
BMI of greater than 30 kg/m2 have a 20% to 34% greater risk of PCa death than men 
with a BMI of 18 to 25 kg/m2 (128). It is thought that obesity may not directly cause the 
onset of PCa, but instead worsen the prognosis and lethality of the disease (129).  
A molecular link connecting PCa development and adipogenesis has not yet been 
extensively studied. One such candidate is leptin. Several reports have shown elevated 
leptin levels in men with PCa (130-132). Saglam et al. measured leptin and PSA levels of 
patients diagnosed with PCa compared to a control group and found significantly higher 
leptin and PSA levels in the PCa group. (130). However, others have not found any 
association between leptin and PCa (133). In vitro, leptin has been demonstrated  by 
several groups to cause proliferation of androgen-independent PCa cells (129,134-138). 
The presence of the leptin receptor mRNA splice variants, human OB-Ra and human OB-
Rb, in PCa cell lines and their expression levels in response to various leptin treatments 
have been documented (138). A possible mechanism of how leptin can directly stimulate 
PCa growth is by inducing high expression of vascular endothelial growth factor 
(VEGF), which is a potent mitogen and can stimulate migration, angiogenesis, and 
microvascular permeability (129). VEGF has been shown to correlate with tumor stage, 
grade, and clinical outcome in PCa and is also expressed in androgen independent PCa 
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cells (139,140). Further work is needed to conclusively assess the possible role of leptin 
in PCa. 
Finally, expression of lipogenic enzymes like FAS is as previously described 
highly upregulated in PCa (21). Fatty acids have obviously a important function for 
cancer growth and maybe the high level of lipogenesis in cancer cells reflects the high 
rate of membrane synthesis in rapidly dividing cells as proposed by Johannes Swinnen et 
al. (21). Is lipogenic overexpression in prostate associated with higher accumulation of 
fat in adipose tissue triggered by obesity? So far, it is too early to conclude and no 
association between FAS expression in adipocytes and prostate tissue has so far been 
reported.  
 
Aim of the study 
As documented in the introduction presented above, prostate cancer and obesity 
are two major health problems facing the Western world. It was recently proposed that 
there is a molecular connection between increasing amounts of adipose tissue and 
progressive growth of the prostate. A description of some candidates have been 
introduced but most likely there are several other factors restricted to prostate or adipose 
tissue that influences the biochemical and genetic milieu in these tissues that may give 
rise to these pathologies. Towards this end, the goal of this master project was to identify 
genes that are regulated by androgens in the prostate cancer cells and during adipocyte 
differentiation.  
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Summary 
Prostate cancer (PCa) and obesity are currently two of the most prevalent health problems 
in the western world. Some epidemiological studies suggest a connection between PCa 
and fat intake and obesity. In addition, androgens, which are required for prostate growth 
and maintenance, as well as being necessary for the beginning stages of PCa, induce 
lipogenic phenotype and gene expression profile in PCa cells. Furthermore, androgens 
play a regulatory role in fat cells. We therefore hypothesized that there are common gene 
expression patterns between prostate and adipocytes.  To assess this possibility, we used 
cDNA microarrays made from a prostate enriched library to identify genes that are 
commonly regulated by androgens in the PCa cell line LNCaP and during differentiation 
of 3T3-L1 cells into adipocytes.  This screen identified Humanin (HN) and Bax Inhibitor 
1 (BI-1) as two such genes, and their expression profiles were verified by quantitative 
RT-PCR.  HN was found to be upregulated during adipogenesis and dose-dependently 
regulated by androgen in LNCaP cells.  BI-1 was only slightly regulated by androgen in 
LNCaP cells and not regulated during adipogenesis in 3T3-L1 cells.  A HN specific 
antibody was used to detect the predicted 3kD peptide in prostate and adipocyte cell 
extracts.  In both tissues, we identified a peptide of 10 kD which is likely due to post-
translational modification of the HN peptide in these tissues.  Further studies are needed 
to assess the functional role of HN in these tissues. 
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Introduction 
PCa is the most common type of cancer among men in Norway with 2841 new reported 
incidence in 2001 (1). In 2005, PCa is predicted to be the cause of death for 30 350 men 
in the United States and therefore the second leading cause of cancer death (2). The 
incidence rate of PCa varies significantly among various race groups. These could be 
explained by differences in environmental exposure, detection rate and methods, genetics 
and in particular dietary factors (3).  High fat consumption has been reported to be one of 
the most important dietary factors which influences prostate cancer onset (4). Studies on 
human PCa mouse models have demonstrated that high fat diet gives rise to a 
substantially more aggressive PCa type (5). Epidemiological studies have been more 
inconsistent, but several studies report a positive correlation between consumption of 
dietary fat and increased risk of PCa (3). Accordingly, it has been hypothesised that obese 
men have a higher risk for developing PCa. Recently, three large studies found this to be 
the case but another report has found an inverse association for the age group <60 yrs or 
those with family history of PCa (6).  Taken together, a growing body of evidence 
suggests that obesity may impact upon risk, detection and outcome with regard to 
prostate cancer. Obesity is a global epidemic affecting an staggering number of people 
each year and is an ever-spreading disease predicted to cause a decline in life expectancy 
during the 21st century (7,8). It is therefore important to enhance our molecular 
understanding of the link between PCa and obesity. Toward this end, we sought to 
identify genes that are expressed and regulated in prostate cancer progression and 
adipocyte differentiation.  Using a prostate-specific microarray, we identified two 
candidate genes, Humanin (HN) and Bax Inhibitor 1 (BI-1) which fit this description and 
may therefore elucidate a link between prostate cancer and obesity.   
HN is a 3 kD short anti-apoptotic peptide initially discovered from a cDNA 
library prepared from the occipital lobe of an autopsy-confirmed Alzheimer Disease 
(AD) brain (10,11). Death trap screening, which is a functional screening strategy to 
identify molecules that enable dying cells to survive (12), was used to identify HN as a 
gene that suppressed neuronal cell death. In this physiological context, HN is secreted 
from neuronal cells and stimulates extracellular cell receptors to induce intracellular 
signalling pathways (11). The receptor for HN is reported to be the G-protein-coupled 
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formylpeptide receptor-like-1 (FPRL1) (13). In the context of Alzheimer’s disease, HN 
competes for binding to the 42-aa beta amyloid peptide, Aβ(42), receptor which induces 
plaque and neuronal death. HN can also act intracellularly by directly binding and 
inactivation of the pro-apoptotic Bcl-2 family members Bcl-2 associated X protein (Bax), 
Bid, or the extra long isoform of Bim (BimEL), thereby rescuing cells from programmed 
cell death (14-16).  
The coding origin for transcription and translation of HN is not clear because 
DNA sequences homologous to HN have been found both in the nuclear genome and in 
the small genome of mitochondria (17). Two different theories for HN expression have 
although been postulated. Based on the homology between HN cDNA and mitochondria 
DNA (i.e., 99% similarity to the coding region of 16S rRNA in the mitochondrial 
genome) it is possible that the HN peptide is an artificial protein encoded by a non-
functional ORF in 16S rRNA. If this is the case, the HN-open reading frame (ORF)-
corresponds to the 16S rRNA containing a poly-A tail. An early study support this 
possibility by demonstrating that all mitochondrial rRNA transiently attach a polyA tail 
during transcription (18). The short HN-ORF of 75 bases, which encodes the 24 amino 
acid peptide, is located 950 bases downstream of the 5′ end of the cDNA. Since there are 
at least seven putative in-frame ORFs in this 5’ region each with a termination codon 
(17), it is also possible that alternatively transcribed forms of HN exist, although this has 
not been thoroughly investigated. The HN sequence is 92–95% homologous to regions in 
the human chromosomes 5, 11, and X (11). Therefore, the source of HN cDNA may be 
nuclear and the HN peptide natively produced from HN mRNA (17). Indeed, some of the 
HN-ORFs are 99% identical to certain registered human mRNAs. In this case, since most 
cells contain poly-A 16S rRNA, the HN-ORF contains a mixture of HN mRNA and poly-
A 16S rRNA. So far it is evident that transcriptional activation of the long HN cDNA 
leads to the production of HN peptide in mammalian cells, despite its unusual structure 
for peptide production. Immunoblots of various mouse tissues show that the HN peptide 
in vivo can be detected in testis and colon of three week old mice but only in the testis of 
12 week old mice (17). Protein expression is also detected in the occipital lobe of AD 
patients. Despite this, it is still unclear if HN is expressed in physiologically functional 
levels in vivo in humans (19).  
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BI-1 was initially cloned from an adult rat testis and also referred to as testicular 
enhanced gene transcript (TEGT) (20,21). It was renamed when a functional screening 
for human proteins that suppresses cell death in yeast induced by ectopic expression of 
mammalian Bax, identified BI-1 as a anti-apotototic protein (22). BI-1 is well conserved 
in animals and plant species, and BI-1 like protein sequences have been found in 
unicellular eukaryotes supporting the hypothesis that BI-1 was as an ancient suppressor 
of programmed cell death (23). BI-1 is overexpressed in breast and prostate malignant 
tumours and down regulation of BI-1 by small interfering RNAs (siRNA) promotes 
apoptosis in LNCaP, DU-145 and PC-3 cells (24). Gene ablation studies of BI-1 show 
that BI-1 suppresses Bax activation through an apoptotic pathway linked to endoplasmic 
reticulum (ER) stress (25).  It has also been hypothesized that BI-1 block the transmission 
of death signals or signals from damaged ER/Golgi to the mitochondria.   
In this study we show the expression profile of HN and BI-1 in the androgen 
dependent PCa cell line LNCaP and the murine adipocyte cell line 3T3-L1.  We also 
provide evidence for in vivo expression of the HN peptide in LNCaP and 3T3-L1 cell 
lines. The functional role for HN in vivo in these tissues is discussed.  
 
Materials and Methods  
Cell cultures and treatment 
The human prostate cell line LNCaP was obtained from the American Type 
Culture Collection (Rockville, MD). All cells were routinely maintained in RPMI 1640 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS), 5 mg/ml 
penicillin/streptomycin, and 200 mM L-glutamine. The cells were incubated at 37°C in a 
humidified 5% CO2, 95% air incubator. The passage number of LNCaP cells was 20–25. 
For androgen induction cells were serum starved for 48 h in RPMI containing 2% 
charcoal-treated (CT)-FCS to remove steroids, followed by 24 h in RPMI containing 
0.5% CT-FCS. The synthetic androgen R1881 (10−8 M) (Dupont-NEN) was then added 
and cells were collected at indicated time points. Control cells were stimulated with 
vehicle (ethanol) only. Tunicamycin treatment was conducted in non-starved LNCaP 
cells. Three different concentrations of chemical (purchased from Sigma) or vehicle 
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(ethanol) was added to 80% confluent cells and incubated for 24h or 48h.  3T3-L1 cells, 
also obtained from ATCC, were grown in monolayer culture in DMEM supplemented 
with 10% FCS. Confluent 3T3-L1 fibroblasts were differentiated to adipocytes in DMEM 
containing 10% FCS, 0.5mM isobutylmethylxanthine (IBMX), 1 µM dexamethasone, 
and 5µg/ml insulin for two days (all purchased from Sigma Aldrich). After 48h, cells 
were reefed with DMEM supplemented with 10% FCS and 100ng/ml insulin for an 
additional 12 days when typically 60-80% of the cells exhibited adipocyte morphology. 
For all cell types, RNA pellets were isolated with TRIzol (Invitrogen) at indicated time 
points. 
 
Oil Red O staining 
Adipogenesis was measured at indicated time points using the triglyceride-
specific dye, Oil red O (Sigma-Aldrich). Cells were fixed in 0.5% gluteraldehyde/PBS 
and stained with 0.15% Oil red O until aggregates start to precipitate (approximately 15 
minutes), and then rinsed with distilled water prior to photography using a phase contrast 
microscope (Olympus).   
 
cDNA Microarray analysis 
Microarray slides were made in-house (The Norwegian Radium Hospital –
University of Oslo microarray consortium) from a prostate specific library (26). Total 
RNA was isolated from cells with TRIzol (Invitrogen). RNA concentrations were 
determined spectrophotometrically and RNA integrity was confirmed by 1% agarose gel 
electrophoresis. RNA was collected from untreated LNCaP (control, 0h), cells stimulated 
with R1881 for 6h and 24h. RNA was collected from 3T3-L1 cells at 2 days pre 
induction (control) or 4 and 2 days post induction. For each experiment, cDNA was 
synthesized from 15µg total RNA from the reference sample and labelled with Cy3 (GE 
health) using SuperScriptII (Invtrogen). cDNA was synthesized from 15µg total RNA 
from the test samples and labelled with Cy5 (GE health) using SuperScriptII (Invitrogen). 
Excess dye was removed with BIO Spin 6 columns (Bio-Rad, Hercules, CA). These two 
labelled populations of cDNA were then mixed and hybridized manually to the pre-
hybridized microarray slides overnight at 65°C.  After washing the slides two times with 
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0.2 µm-filtered 0.5x SSC, 0.01x SDS, 10-3M DTT solutions and two times with 2µm-
filtered 0.06 X SSC, 10-3M DTT solutions, the slides were scanned and visualized with a 
GenePix 3000 scanner (Axon Instruments). Finally, the results were computationally 
analyzed with Bio Array Software Environment (BASE), and all genes commonly 
expressed in both 3T3-L1 and LNCaP were selected and clustered.  
 
cDNA synthesis and quantitative real-time RT-PCR 
 1 to 5 µg of total RNA was DNase-treated with RNase-free DNase I (Promega) 
before total RNA was precipitated with ammonium acetate and ethanol to inactivate the 
DNase, and processed for cDNA synthesis by SuperScript II (Invtirogen). Primers used in 
real-time PCR was designed by the primer design program, Primer3 (27). Information of 
primers is enclosed in table 1. Real time PCRs were analyzed by Light Cycler 
instrumentation (Roche) in capillaries with 10µl reaction volumes containing 0.25x 
LightCycler® FastStart DNA Master SYBR Green I (Roche Diagnostics), 2-4 mM 
MgCl2, 0.5 µM of each primer, and 1 µl of cDNA template. MgCl2 concentrations and 
temperature conditions were optimized for each primer pair. Cycling conditions included 
an initial denaturation step at 95  °C for 10 min, followed by 45 cycles of 95°C 
denaturation for 10 sec, 62-66°C annealing for 5 sec (see table 1), and 72°C extension for 
20 sec.  A negative control reaction in the absence of template was also performed for 
each primer pair. Melting curve analysis was performed for each reaction to confirm 
exclusion of non-specific PCR by-products. Dilution standard curves were used as 
external standards. For each sample, the ratio between the relative amounts of target gene 
and housekeeping gene was calculated to compensate for variations in the quantity or 
quality of the starting mRNA as well as for differences in reverse transcriptase efficiency. 
The change in fluorescence of SYBR Green dye in every cycle was monitored, and the 
crossing point (CP) values, defined as the points at which the fluorescence increased 
appreciably above background was used to determine the relative expression of the gene 
of interest. All gene quantities were normalized to a housekeeping gene. In 3T3-L1 cells 
36B4 was used as housekeeping gene and ATP-6 was used in LNCaP cells. All data 
analysis was performed with Excel (Microsoft). 
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Western blotting 
Protein tissue samples were prepared by homogenization of mouse testes or 
subcutaneous adipose tissue (kindly provided by Arne Klungland, The National Hospital, 
University of Oslo, Norway) with lysis buffer [0.5% Triton X, 50mM Tris/HCl (pH7.5), 
1mM EDTA]. After centrifugation, the supernatant was mixed with reducing SDS sample 
buffer [187.5mM Tris-HCl (pH 6.8), 6% SDS, 30% glycerol, 0.03% phenol red, 1.25M 
DTT]. Whole cell extracts from LNCaP and 3T3-L1 cells were prepared by resuspending 
the cells in 50-100 µl of lysis buffer [10mM Tris-HCl(pH 7.5), 1mM EDTA, 1% Triton 
X-100 and 0.5 mM PMSF]. The suspension underwent two freeze-thaw cycles, followed 
by centrifugation at 13000rpm for 10 min at 4° C. The supernatant was collected and 
stored at –80°C. All protein concentrations were determined by the Bio-Rad protein 
assay. Reducing SDS sample buffer [187.5mM Tris-HCl (pH 6.8), 6% SDS, 30% 
glycerol, 0.03% phenol red, 1.25M DTT] was mixed with protein extracts at room 
temperature over-night before the samples were electrophoresed on a 16% separating, 
10% spacer and 4% stacking SDS-PAGE gel. A Precision Plus Protein dual protein 
standard (Bio-Rad) was used to decide the molecular weight of the bands. The proteins 
were transferred to a PVDF membrane (Bio-Rad) soaked in 10mM 
cyclohexylaminopropanesulfonic acid (CAPS) (Sigma) and 10% methanol transfer 
buffer. The blotted membrane was blocked with 10% milk for 1 h, followed by 
incubation with the primary antibody at 4°C overnight. The antibodies used are anti-
Humanin rabbit polyclonal antibody (1:2500 dilution) (a generous gift from Ikuo 
Nishimoto, Department of Pharmacology and Neurosciences, Keio University School of 
Medicine, Tokyo, Japan), anti-PSA goat polyclonal antibody (1:200) (Santa Cruz 
Biotech), anti-Tubulin (1:1000) monoclonal mouse antibody (Sigma Aldrich), 
Horseradish peroxidase (HRP) conjugated to anti-mouse IgG (Sigma Aldrich), HRP 
conjugated to anti-rabbit IgG (Sigma Aldrich), and HRP conjugated to anti-goat IgG 
(Santa Cruz Biotech.) PSA goat monoclonal antibody (1:200 dilution), Tubulin mouse 
polyclonal antibody (1:2000), aP2 polyclonal antibody (1:2000) (a generous gift from 
Gökhan Hotamisligil, Department of Genetics and Complex Diseases, Harvard School of 
Public Health, Boston, Massachusetts, USA). The enhanced chemiluminescence kit 
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(Amersham Pharmacia) was used for detection according to the manufacturer’s 
recommendations.  
 
Competition assay  
A synthetic HN peptide (MAPRGFSCLLLLTSEIBLPVKRRA) (Sigma Aldrich) 
and KLK4 NH2-terminal peptide (QIINGEDCSPHSQPW) (Medprobe) was dissolved in 
1 x TBS/0.1% Tween. 150µg peptide was pre-incubated with 1:2500 HN-Ab for 1 hour 
rotating at 4°C before incubated with western blot membranes.  
 
TABLE 1. Information of primer used in experiments.  
 
 
Name Annealing 
temp (°C) 
[MgCl2] 
(mM) 
Sequence 
HN (human) 66 4 Forw: 5’-  aaacctaccgagcctggtga – 3’ 
Rev: 5’-  ggcttatgcggaggagaatg – 3’ 
HN (mouse) 64 3 Forw: 5’- taccctaaccgtgcaaaggt – 3’ 
Rev: 5’-  aagctccatagggtcttctc -3’ 
BI-1 (human) 64 3 Forw: 5’- gcatccttcccactgctttc – 3’ 
Rev: 5’- ccatgttcggccttttcaat -3’ 
BI-1 (mouse) 64 3 Forw: 5’- cccacataactccctcgaca -3’ 
Rev: 5’- aaggttccccagagaggaca -3’ 
36B4 64 3 Forw: 5’- aagcgcgtcctggcattgtct -3’ 
Rev: 5’- ccgcaggggcagcagtggt -3’ 
ATP-6 62 3 Forw: 5’- cagtgattataggctttcgctctaa -3’ 
Rev: 5’- cagggctattggttgaatgagta -3’ 
aP2 64 3 Forw: 5’- ggtcaccatccggtcagagag -3’ 
Rev: 5’- tcgactttccatcccacttc -3’ 
PSA 66 4 Forw: 5’- ccctgagcacccctatcaac -3’ 
Rev: 5’- tgagtgtctggtgcgttgtg -3’ 
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Results 
Identification of Humanin and Bax Inhibitor 1-expression in LNCaP and 
3T3-L1 cells by microarray analysis 
To identify new candidate genes that are expressed and regulated during 
adipocyte differentiation and PCa development we took advantage of a prostate specific 
library (PSL) that previous laboratory members had constructed (26).  Since adipose 
tissue was not among the tissues that were subtracted from the prostate DNA, we 
expected to identify adipose tissue genes among those identified through this screen. All 
the cDNA sequences from the PSL were spotted onto microarrays plates (The DNR-UiO 
Microarray Core Facility). To identify genes relevant to prostate cell progression and 
adipocyte differentiation, RNA was harvested from untreated or androgen-treated LNCaP 
cells, and undifferentiated and differentiated 3T3-L1 cells. Upregulation of PSA gene 
expression in response to androgen was used to verify androgen activation of LNCaP 
cells, as shown in Figure 1A. Gene expression analysis and lipid staining was used to 
confirm differentiation of pre-adipocytes into mature adipocytes. Upregulation of 
adipocyte-specific fatty acid binding protein (aP2) mRNA were determined by 
quantitative real–time RT-PCR. aP2 is induced early in adipogenesis by the transcription 
factor Peroxisome Proliferator Activated Receptor γ (PPAR γ) (30). As shown in Figure 
1B, the levels of aP2 mRNA increased during adipocyte differentiation beginning at day 
4 post induction. Oil red O staining of fixed 3T3-L1 cells upon differentiation show 
accumulation of lipid by red staining of triglycerides and cholesteryl oleate (31). Pictures 
of the cells during differentiation show that pre-adipocytes initially harbour very small 
amount of lipid droplets, but accumulates significant amounts only 4 days after induction 
(Figure 1C).  
RNA extracts from androgen stimulated LNCaP cells and differentiated 3T3-L1 
cells were then used in microarray experiments to determine differences in gene 
expression induced by R1881 or during adipogenesis, respectively. We measured 
expression ratios of 0h vs. 6h and 0h vs. 24h of R1881 treatment in LNCaP cells, and -2 
days vs. +4 days and -2days vs. +12 days in differentiated 3T3-L1 cells. Analysis of the 
scanned hybridized microarray slides by the BASE software (32) showed that 713 cDNA 
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sequences were expressed and/or regulated in both tissues (Figure 2). Clones in the PSL 
library corresponding to these genes were PCR amplified using T7 and SP6 primers. 
After PCR purification, the samples were sequenced and the sequencing data were 
analysed with the BLAST tool (http://www.ncbi.nlm.nih.gov/BLAST/). Some of the 
clones that we sequenced are listed in Table 2. The criterion in our microarray clustering 
analysis was that only genes expressed in LNCaP and 3T3-L1 cells were subjects of 
interest. Literature searches were conducted on certain genes identified by this screen to 
confirm that these genes have previously been shown to be highly enriched in the prostate 
and androgen regulated. The microarray analysis showed that PSA cDNA was highly 
upregulated in LNCaP cells, but not expressed in 3T3-L1, demonstrating the integrity of 
the samples used in this analysis and the ability of the bioinformatics analysis to 
selectively choose androgen- regulated genes. Curiously, we also identified many other 
genes known to be expressed ubiquitously and previously not known to be androgen 
regulated (e.g. MDM2 and RGS10).  Based on the obtained data, we were particularly 
interested in further investigating Humanin (HN) as a candidate link between prostate 
cancer and obesity because it is positively regulated by androgen in LNCaP cells and 
during differentiation of 3T3-L1 cells. Bax Inhibitor 1 (BI-1) was also selected as a 
negative control because of it plays a similar role as HN in apoptosis, but was neither 
regulated by androgen in LNCaP cells or during adipogenesis.  
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0 day
+4 day
+8 day
C  
FIGURE 1 – Verification of activated AR in LNCaP and complete differentiation of 3T3-L1 cells.  
 A) PSA is induced by androgens in LNCaP cells. Cells were treated with 10-8M R1881 synthetic androgen 
for indicated time points. Isolated total RNA was converted to cDNA and PSA expression (relative to ATP-
6 expression) was measured by quantitative real-time RT-PCR. The average of three independent 
experiments each in triplicate +/-SE is shown.  B) aP2 is induced in 3T3-L1 four days after induction of 
adipogenesis. Isolated total RNA was converted to cDNA and aP2 expression (relative to 36B4 expression) 
was measured by quantitative real-time RT-PCR. The result presented is the average of three independent 
experiments +/- SE. C) Fatty acids accumulate during adipogenesis in 3T3-L1 cells. Cells differentiated for 
0, 4 and 8 days were fixed and stained with OilRed O. The left pictures are photographs at 20x 
magnification. Red dots show staining of accumulating fat. 
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FIGURE 2 – HN and BI-1 are expressed in LNCaP and 3T3-L1 cells.  
RNA was collected from untreated LNCaP cells (reference, 0h), or cells stimulated with R1881 for 6h and 
24h. RNA was collected from 3T3-L1 cells at 2 days pre induction (reference) or 4 and 12 days post 
induction. cDNA was synthesized from 15µg total RNA from the reference and test sample and labelled 
with Cy3 and Cy5, respectively by SuperScriptII enzyme. The samples were manually hybridized on the 
slides at 65C overnight, washed, scanned by a GenePix3000 scanner and analysis was performed using the 
BASE software. The figure shows two pieces of the obtained clustering map identifying HN and BI-1. HN is 
highly upregulated in 12 days differentiated 3T3-L1 cells but not in LNCaP cells. BI-1 is not regulated.       
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Name Clone 
number 
Accession 
number  
3T3-L1 LNCaP 
Humanin PL B12 AY029066 Up regulated Weakly up 
BI-1 FE F10 NM_003217 Not 
regulated  
Not 
regulated 
MDM2 BC C10,  CC 
E1, HC D7, JB 
B2 
NM_006879 Weakly up Weakly 
down 
RGS 10 EB A11, EC 
A8, EE D3, IB 
D9, JB E2 
NM_001005339 Weakly up Down 
regulated 
PSA AE E10, BF 
A2, CE E11, 
CK A6 
NM_001002231 Not detected Upregulated 
TABLE 2. Some of the clones identified by the microarray experiments.  
MDM; murine double minute-2, RGS 10; regulators of G-protein signalling 10.   
 
HN and BI-1 are expressed in LNCaP and differentiated 3T3-L1 cells 
To verify the microarray data of HN and BI-1 and to more accurately quantify 
their regulation, we analyzed the relative expression of these by quantitative real-time 
PCR. Gene quantities were normalized to relevant housekeeping genes which are 
expressed at stable levels in each cell type. The mitochondrial gene ATP synthase 6 
(ATP-6) has previously been used as a housekeeping gene in LNCaP cells (33) and our 
results confirm those studies (see Figure 3A, left panel). In 3T3-L1 cells the ribosomal 
protein 36B4 has been shown to be not regulated during adipogenesis (34) and our results 
confirmed this (Figure 3A, right panel). HN is expressed and upregulated 5-fold four 
days after induction of differentiation in 3T3-L1 cells (Figure 3B, right panel).  In LNCaP 
cells no significant time-dependent regulation of androgen was seen (Figure 3B, left 
panel). However, HN expression was down regulated in a dose-dependent fashion in 
LNCaP cells treated with various concentrations of R1881 (10-12M to 10-8M) for 24h 
(Figure 3C, left panel). As a positive control, expression of PSA was assessed which 
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increased in a dose dependent fashion (Figure 3C, right panel). Expression levels of BI-1 
mRNA were also determined in LNCaP cells treated with 10-8M R1881 at various 
timepoints, or during differentiation of 3T3-L1 cells.  In agreement with the microarray 
analysis we found that BI-1 is not regulated during adipogenesis (Figure 3D, left panel) 
and only slightly induced, approximately two-fold, by androgen in LNCaP cells (Figure 
3D, right panel).  
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FIGURE 3.HN is regulated during adipogenesis in 3T3-L1 cells and dose-dependently in LNCaP cells. BI-
1 is only slightly regulated during R1881 stimulated LNCaP cells and not during adipogenesis in 3T3-L1 
cells.  
A) ATP-6 (left) and 36B4 (right) are expressed in equal levels in androgen treated LNCaP and 3T3-L1 
differentiated cells, respectively. B) HN is not time-dependently induced by androgens in LNCaP cells (left 
panel) but upregulated during adipogenesis in 3T3-L1 cells (right panel).  C) Dose-dependent androgen 
treatment of LNCaP cells show a dose-dependent increase of PSA expression (right panel) and increase of 
HN expression from 10-12 to 10-8M (left panel). Cells were treated with indicated concentrations of R1881 
for24h. Isolated total RNA was converted to cDNA and HN expression (relative to ATP-6 expression) was 
measured by quantitative RT-PCR. The average of two independent experiments +/-SE is shown. D) BI-1 
expression is induced in LNCaP R1881 treated cells (left panel). BI-1 is not regulated during 3T3-L1 
adipogenesis (right panel) but regulated two fold in LNCaP cells after 24h (left panel). For A, B and D 
LNCaP cells were treated with 10-8M R1881 androgen for indicated time points. Isolated total RNA was 
converted to cDNA and HN expression (relative to ATP-6 expression) was measured by quantitative real-
time RT-PCR. The average of three independent experiments each in triplicate +/-SE is shown.  3T3-L1 
cells were differentiated and isolated total RNA from indicated time-points during differentiation were 
converted to cDNA. Gene expression (relative to 36B4 expression) was measured by quantitative real-time 
RT-PCR. The result presented is the average of three independent experiments +/- SE. 
 
HN is detected as a 10kD peptide in LNCaP and 3T3-L1 cells  
To investigate whether the HN mRNA was functionally translated to protein in 
PCa cells and adipocytes we examined whole cell extracts of LNCaP cells or 
subcutaneous adipose tissue by Western blot analysis using a HN antibody previously 
shown to detect this peptide in testes and colon (17). Protein extracts from testes of five- 
month old mice was prepared and used as positive control samples. As expected, HN was 
detected in the testes with a size of approximately 3kD (Figure 4A). A strong 10 kD band 
was detected in LNCaP extracts and a weaker band at the same size was observed in 
adipose tissue (Figure 4A). In testes we also see a band of 10kD (Figure 5 and 6).  
To examine protein expression of HN in response to R1881, LNCaP cells were 
treated with R1881 for different time points. As expected, we see the same regulation of 
PSA at the protein level as we saw at the mRNA level (Figure 4B, upper panel). When 
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the same membrane was stripped and probed with HN antibody, we detected a strong 
band at approximately 10kD that was not regulated by androgen over time (Figure 4B, 
middle panel). Equal protein loading was confirmed by examination of tubulin protein 
expression (Figure 4B, lower panel).  
A 10kD band was also detected in 3T3-L1 adipocytes differentiated for 4 and 12 
days (Figure 4C). Proper differentiation of adipocytes was confirmed by aP2 protein 
expression.  
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FIGURE 4. A signal of approximately 10kD is detected in LNCaP and 3T3-L1 cells with a HN antibody.  
A)  Protein extracts from untreated LNCaP cells (200µg), murine testes tissue(50µg) or subcutaneous 
adipose tissue(200µg) was collected and analyzed by Western blotting. A highly expressed band of 
approximately 3kD was detected with a HN-Ab in testes but not in adipose tissue and LNCaP cells. A 10kD 
band is strongly expressed in LNCaP cells and weakly in adipose tissue. B)  PSA is regulated at the protein 
level in LNCaP cells but the 10kD band is not. LNCaP cells were charcoal treated and incubated with     
10-8M R1881 at indicated time points. Cell extracts were collected and probed with PSA, HN or Tubulin 
antibodies using the same membrane. C)  A 10kD band is weakly detected in 3T3-L1 cells. +4 and +12 day 
3T3-L1 adipocytes cell extracts were collected and probed with HN, aP2 or tubulin antibodies.    
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HN antibody specifically recognizes the observed bands at 3kD and 10kD  
Although HN has not been previously shown to be translated into a 10kD product, 
it is possible that HN undergoes unique post-translational modifications in LNCaP and 
3T3-L1 cells. To rule out the possibility of non-specific binding by the antibody used, we 
titered the HN antibody pre-incubating it with the same peptide used for immunization of 
the rabbits in preparation of the antibody. Co-incubating with 150 µg of synthetic HN 
peptide resulted in complete loss of the 10kD band from LNCaP and testes extracts and 
almost complete loss of the 3kD band in testes (Figure 5, right panel), but no differences 
occurred when 150 µg of a control KLK4 peptide was co-incubated with HN antibody 
(Figure 5, middle panel). From this, we conclude that HN is functionally translated in 
LNCaP cells, but may be modified with post-translational moieties.  
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FIGURE 5. HN antibody is specific for the 10kD modified form of Humanin. 
Triplicates of protein extracts from testes (50µg) and untreated LNCaP cells (200µg) were loaded to the 
same gel and blotted .The membrane was cut in three separate pieces and incubated with HN-Ab only, HN-
Ab pre-incubated with 150 µg hK4 peptide or HN-Ab pre-incubated with 150 µg synthetic HN peptide. The 
membrane to the right activated the ECL solution stronger than the other two membranes but despite 
strong background the 10kD band disappears and the 3kD band is significantly reduced in strength 
compared to controls.   
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The 10kDa HN peptide is most likely not a dimer/trimer or glycosylated 
We further investigated the reason for the significant size difference between HN 
in testes versus LNCaP and 3T3-L1 cells. Since the protein extracts used in these 
immunoblots were not denatured by heat, we tested the impact of using a stronger 
detergent and of boiling the extracts. Surprisingly, the 10kD band disappears upon 
heating or usage of the strong detergent 2-mercapthoethanol (Figure 6A), suggesting 
alteration of its secondary structure. We then hypothesized that HN could be glycosylated 
since it has previously been found to be secreted from cells transfected with a HN 
expression plasmid, as well as in F11 cells which are hybrid cells of E13 rat primary 
neuron with mouse neuroblastoma NTG18 cell (11). Addition of sugar chains during 
transport in the Golgi network prior to exocytosis could explain this increase in size. 
Tunicamycin is a well established as an inhibitor of glycosylation. Untreated LNCaP 
cells were therefore incubated with different amounts of tunicamycin or vehicle. PSA has 
previously been reported to be glycosylated and tunicamycin treatment reduces the 
detected size of PSA compared to untreated cells in LNCaP extracts (Figure 6 B, middle 
panel). However, the 10kD HN band did not exhibit a mobility shift upon tunicamycin 
treatment, indicating that glyosylation is not the reason for the increased protein size. The 
strength of the band was, however, weaker in tunicamycin-treated cells indicating that 
glycosylation or other functions of the compound do affect the expression of HN. 
Investigations to unveil reasons for the increased protein size are ongoing.  
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FIGURE 6. 10kD HN is lost when heated and during tunicamycin treatment in LNCaP cells.  
A) Heat and treatment with a strong detergent result in loss of the 10kd HN form in LNCaP but not in 3kd 
HN from testes.  Testes (50µg) or LNCaP (200µg) extracts were incubated with DTT (normal procedure) or 
2-Mercaptoethanol at room temperature overnight or boiled at 95ºC for 3 minutes before analyzed by 
Western blotting. B) PSA is deglycosylated in LNCaP cells but HN is not. Indicated amounts of 
tunicamycin or vehicle control (MQ) were added to LNCaP for 24h hours. Extracts were analyzed by 
Western blotting with testes tissue as control. The same membrane was incubated with PSA, HN and 
tubulin Ab. Band shift was detected for PSA in tunicamycin positive cells but not in control indicating that 
glycosylation is inhibited. With HN-Ab no size differences are detected indicating that HN not is 
glycosylated.  C) Humanin expression is inhibited by tunicamycin. The same cell extracts from B) analyzed 
by Western blotting probed with HN-Ab shows that tunicamycin inhibits translation of 10kD HN in LNCaP 
cells.   
 
Discussion 
We have used a prostate-enriched cDNA library in microarray analysis to identify 
genes that are commonly expressed in adipocyte and PCa cell lines. Our high-throughput 
screening approach identified 713 cDNA clones which are expressed in both adipose and 
PCa cell lines. Of the genes that were identified, the work reported here has focused 
especially on HN and BI-1. Neither of these two genes exhibit tissue-specific expression 
in prostate and adipose tissue. However, Korkmaz et al. found in their initial report using 
the PSL library that of the 117 clones they investigated 76% were largely specific to the 
prostate for expression, and of these, approximately 40% were previously shown to be 
under androgen regulation (26). It is therefore no surprise that we detect genes that are 
not prostate specific among the thousands of clones that we investigated. In fact, since 
many clones housing common housekeeping genes were subtracted when the library was 
made the possibility for finding new candidates in our experiments may have increased. 
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On the other hand, elimination of these housekeeping genes may hastily have ruled out 
genes that might be relevant to both prostate cancer and adipogenesis, such as adhesion 
molecules, structural genes, or genes related to transformation or cell cycle. 
We found BI-1 and HN particularly interesting because they have both been 
reported to inactivate the highly studied pro-apoptotic Bax and therefore behave like 
oncogenes (14,25).  Evasion of programmed cell death or apoptosis is one of the well 
established hallmarks of cancer (35). Importantly, oncogenes are gene variants that 
stimulate cancer growth often through involvement in apoptotic evasion (36). Apoptosis 
during adipogenesis has not been established to the same degree as in PCa cells, although 
there is some evidence indicating that apoptosis indeed plays an important role in 
regulation of involution of adipose depots under certain conditions. Previously it was 
believed that adipocyte acquisition was permanent and that weight loss caused a decrease 
in cell size only (37). It is now hypothesized that adipocyte acquisition is balanced by a 
process also including cell deletion (38-40). 
 BI-1 was previously shown to be expressed at higher levels in PCa patients than 
in healthy subjects (24), but its functional role in PCa development is not known.  In 
microarray analysis (Figure 2) BI-1 was not regulated in LNCaP cells and we observed 
only a slightly upregulation in LNCaP cells in response to androgen (Figure 3D left 
panel) by quantitative RT-PCR verifications. Further experiments at the protein level 
must be performed before we can conclude regarding the role of androgens in regulation 
of BI-1. In adipocytes we did not observe any significant regulation during adipogenesis 
(Figure 3D right panel). Still, BI-1 might have vital functions in both tissues. It would be 
interesting to explore if BI-1 is involved in the same ER stress induced pro-apoptotic 
pathway in PCa tissue as Chae et al. reported for liver and brain (25).   
Our quantitative measurement of HN mRNA expression levels in 3T3-L1 and 
LNCaP do not disagree with the microarray data (Figure 2 and 3B). Indeed, levels of HN 
gene transcripts increase during adipogenesis. While HN mRNA does not seem to be 
regulated by androgen in LNCaP over time, a dose-dependent response to androgen is 
observed (Figure 3A and 3B). Since HN has sequence identity to the 16S rRNA in 
mitochondria, it is possible that the signals that have been measured are artifactual and 
actually correspond to 16S rRNA levels instead of HN levels. There is also one report in 
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the literature stressing that rRNAs do have a poly-A tail, debunking the general view that 
it only mRNA possess poly-A tails (18). Since we used oligodT primers to extract mRNA 
from the isolated total RNA pool, we did not expect that rRNA would be converted to 
cDNA by the reverse transcriptase. It is important to verify whether rRNAs do have a 
poly-A tail before any conclusion about the mRNA HN expression levels can be made. 
However, our data on HN protein expression do support that our data of HN mRNA 
expression is not artifactual evidence.  
We detected a signal at approximately 10kD in prostate and adipocyte whole cell 
extracts by use of a HN specific antibody (Figure 4A and 4C). We surmise that the 
observed band is a modified form of the 24 amino acid HN peptide natively expressed in 
prostate and adipose tissue. In fact, a 10kD HN band is also detected in testes albeit at 
lower levels than the 3kD form. The competition assay clearly showed that the antibody 
is specific for both the 3kD and the 10kD bands in testes and LNCaP cells (Figure 5).  
We propose that the observed size difference is most likely due to post-translational 
modifications, which have indeed been reported for HN (42). The HN amino acid 
sequence has two serine residues (Ser 7 and Ser 14) that are potential sites for 
glycosylated, phosphorylated or ubiquitinylated. In addition Terashita et al. claims that 
synthetic HN injected into cells self- dimerize. Alteration of Ser14 to Gly14 eliminated 
dimerization and resulted in loss of neuronal cell death protection, indicating that this 
residue is necessary for dimerization, and that this residue is important for proper HN 
function. Normally, non-covalent bonds formed upon dimerization are disrupted by the 
harsh treatment of detergents and heat, which destroy the native structure of proteins. We 
have shown that boiling or incubation with stronger detergents results in degradation of 
the 10kD band in LNCaP cells, suggesting that this band represents a post-translationally 
modified form of HN that is stable at room temperature but unstable under denaturing 
conditions (Figure 6A). Although, we have so far been unable to separate the proposed 
dimer into monomers, we have not ruled out the possibility of a dimerization.  
HN has been shown to be secreted from cells (11). Normally, this process 
involves transport through the Golgi apparatus where glycosylation occurs. If HN in 
LNCaP cells was glycosylated and therefore larger, we expected antibody recognition of 
a smaller HN peptide when tunicamycin inhibits addition of sugar chains. We observed 
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that tunicamycin treatment inhibits the expression of the 10kD protein, however did not 
observe size differences due to glycosylation (Figure 6B and 6C).  Clearly, further 
experiments are necessary to elucidate why HN is expressed in a larger modified form.  
Interestingly, it has recently been reported that the intracellular level of HN is regulated 
through ubiquitin-mediated degradation by the RING ubiquitin ligase TRIM11, which 
binds and facilitates ubiquitination of HN (43). Ubiquitin (Ub) is activated by ubiquitin-
activating enzymes (E1), passed onto ubiquitin-conjugating enzymes (E2), and then 
transferred to ubiquitin ligases (E3) which contain HECT or RING finger domains (44). 
In the light of the observation that the E3 ligase TRIM11 can bind HN, it is tempting to 
speculate that HN is ubiquitinated, although this has not been confirmed in our hands. Ub 
has a molecular weight of 8.5kD and addition of the 3kD expected size of HN results in a 
final product of 11.5 kD which is close to the size of the signal observed in our 
experiments with LNCaP and 3T3-L1 cell extracts. To further investigate whether HN is 
monoubiquitinated immunoprecipitation studies on HN could be performed on LNCaP or 
3T3-L1 cells in conjunction with immunodetection of ubiquitin. Additionally, genetic 
knockdown of TRIM11 by RNA interference (RNAi) may result in a shift in molecular 
weight of HN detectable by Western blotting.  
  It is important to elucidate the exact function of HN in prostate. In addition to the 
already mentioned TRIM11 and the pro-apoptotic Bcl-2 family members Bax, Bak and 
BimEL protein,  yeast two hybrid screening has also demonstrated the interaction of HN 
with insulin-like growth binding protein 3 (IGFBP-3). IGFBP induces and regulates 
apoptosis in various cancer cells, and is implicated in neurological disorders (45). 
Additional studies are required to verify these potential interactions but HN is clearly 
involved in several independent pathways associated with cell death suppression.  
After Guo et al. reported that HN inactivated Bax (14), HN attracted much 
attention. Bax is an essential protein which participates in cell death during normal 
development and in various diseases (46). It is known that Bax resides in an inactive state 
in the cytosol of many cells. In response to death stimuli, Bax protein undergoes 
conformational changes that expose membrane-targeting domains, resulting in its 
translocation to mitochondrial membranes, where Bax inserts and causes release of 
cytochrome C and other apoptogenic proteins (47). Although this is an area of intense 
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research, it is still unknown what controls conversion of Bax from the inactive to active 
conformation (14); HN can be important for this conversion. Immunohistochemical 
studies of HN may provide more clues to its possible regulation of Bax. Preliminary 
immunofluorescence (IF) experiments with the HN specific antibody in LNCaP cells 
indicate that HN is located in all areas of the cells (data not shown). It is necessary to 
transfect cells with a transient expression vector containing a HN-GFP (Green 
Fluorescence Protein) construct to validate how specific the antibody is related to IF.   
In conclusion, we have detected expression of the two anti-apoptotic genes HN 
and BI-1 in LNCaP and 3T3-L1 cells. HN mRNA expression is induced during 
adipogenesis, and dose-dependently in LNCaP whereas BI-1 is slightly regulated by 
R1881 in LNCaP cells. We have also observed endogenous expression of HN protein in 
LNCaP and 3T3-L1 cells, and propose that HN is post-translationally modified in these 
cells although further evidence is necessary to elucidate the exact modification involved. 
Future studies are required to elucidate the specific functions of these genes in vivo in 
prostate and adipose cells.  
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